Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Market Cap	61.28B -7.5%
Revenue (ttm)	33.92B +1.7%
Net Income	5.37B +6.1%
EPS	129.00 +6.1%
Shares Out	41.63M
PE Ratio	11.41
Forward PE	15.21
Dividend	50.00 (3.40%)
Ex-Dividend Date	Sep 29, 2026

Volume	170,700
Open	1,475.00
Previous Close	1,475.00
Day's Range	1,458.00 - 1,485.00
52-Week Range	1,067.00 - 2,005.00
Beta	-0.16
Analysts	Buy
Price Target	1,693.50 (+15.05%)
Earnings Date	Nov 10, 2026

About TYO:2395

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,680
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2395

Financial Performance

In fiscal year 2026, TYO:2395's revenue was 32.52 billion, an increase of 0.34% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.27%.

Analyst Summary

According to 2 analysts, the average rating for 2395 stock is "Buy." The 12-month stock price target is ¥1,694, which is an increase of 15.05% from the latest price.

Price Target

¥1,694

(15.05% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error